The American Autoimmune Related Diseases Association takes positions from time to time on health related issues and legislation.
Some of our current efforts:
AARDA is supportive of the 21st Century Cures Act.
Autoimmune diseases need cures. Although there are treatments for many of the autoimmune diseases that can alleviate symptoms, few available treatments actually alter the course of an autoimmune disease. Most treatments for autoimmune diseases must be taken on a continuous basic, often for a lifetime. Although many of the treatments can have serious and undesirable side effects, patients are left with no other choice than to tolerate the treatments as they live with their chronic illnesses. Cures are needed. Research funding is crucial to finding cures.
AARDA supports legislation that holds the promise of future cures and includes reforms that will lessen the time currently seen to achieve effective treatments.
Learn about the act here: https://energycommerce.house.gov/cures
- 6/23/15 Here is one of many letters to which we have lent our name. [Update: The 21st Century Cures Act was overwhelmingly passed by the House on July 10th]
Other efforts on behalf of autoimmune patients:
01/22/16 AARDA submitted a letter regarding the Health Carrier Prescription Drug Benefit Management Model Act, MDL 22
- Comment letter AARDA Comments to NAIC Model Act 012016
10/28/15 AARDA submitted comments to the FDA regarding Nonproprietary Naming of Biological Products; Draft Guidance for Industry.
9/17/15 The US Senate Committee on Health, Education, Labor, and Pensions conducted a hearing to assess the progress of the FDA in implementing biosimilars: “Biosimilars Implementation: A Progress Report from FDA”
7/25/15 AARDA’s president and executive director Virginia Ladd, pens OpEd which appeared in the Editorial Section of the Detroit News.
7/13/15 AARDA cosponsors Biosimilars Briefing on Capitol Hill.
6/23/15 AARDA is supportive of the 21st Century Cures Act. Here is one of many letters to which we have lent our name. [Update: The 21st Century Cures Act was overwhelmingly passed by the House on July 1oth]
6/16/15 AARDA and the NCAPG represents AD patients at the UN World Health Organization meeting in Geneva, Switzerland on June 16, 2015. The meeting was on International Nonproprietary Names (INN) Biological Qualifiers (BQ) to continue its development of a worldwide accepted naming convention for biologic and biosimilar drugs.
6/01/15 AARDA’s Board of Directors approved a Policy Statement on Biologics
3/6/15 AARDA’s Statement on the FDA’s Approval of the First U.S. Biosimilar Drug
3/6/15 AARDA releases paper on Biologics-Biosimilars
- Press Release: BiosimilarsWhitePaperPressRelease
- Read the paper: Biologics-Biosimilars-BookletFINAL